940867-25-4

Basic information

• Product Name: Docetaxel-D9
• Synonyms: Docetaxel-D9;Taxotere-d9;Docetaxol-d9;N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol-d9;RP 56976-d9;DOCETAXEL, d9-(SH)
• CAS NO: 940867-25-4
• Molecular Formula: C43H53NO14
• Molecular Weight: 807.87922
• Product Categories: All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Isotope Labeled Compounds;Pharmaceuticals;Chiral Reagents;Isotope Labelled Compounds
• Mol File: 940867-25-4.mol

Chemical Properties

• Melting Point: 163-165°C
• Appearance: /
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: Docetaxel-D9(CAS DataBase Reference)
• NIST Chemistry Reference: Docetaxel-D9(940867-25-4)
• EPA Substance Registry System: Docetaxel-D9(940867-25-4)

Safety Data

• Hazardous Substances Data: 940867-25-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Docetaxel-D9 is used as an antineoplastic agent for its antimitotic properties, which help in the treatment of various types of cancer by disrupting the normal cell division process and inhibiting tumor growth.
Used in Research and Development:
Docetaxel-D9 is utilized as an internal standard for the quantification of Docetaxel by gas chromatography (GC) or liquid chromatography (LC) mass spectrometry, aiding in the accurate measurement and analysis of the drug in various applications.

Upstream product

• 1383561-36-1 d₉-tert-butylbenzotriazolyl carbonate 
• 133524-69-3 (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-amino-2-hydroxy-3-phenylpropanoyl)oxy)-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate 
• 114915-20-7 Docetaxel 
• 1383572-41-5 3’-aminodocetaxel formate 
• 940867-26-5 2-(tert-[⁽²⁾H₉]butoxycarbonyloxyimino)-2-phenylacetonitrile 

Downstream Products

• 1383561-40-7 d₉-docetaxel-2'-O-alaninate 

Relevant articles and documents

MULTI-ARM POLYMERIC PRODRUG CONJUGATES OF TAXANE-BASED COMPOUNDS

Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of taxane-based compounds and/or fluorinated forms thereof. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the taxane-based compound is achieved.

DEUTERATED AND/OR FLUORINATED TAXANE DERIVATIVES

The invention relates to (among other things) deuterated and/or fluorinated docetaxel and cabazitaxel and derivatives thereof, as well as compositions comprising each of the foregoing.

LABELLED DOCETAXEL

There are provided deuterated docetaxel derivatives, characterized in that the isotopes are present in the tert-butoxy group. More particularly, one or more of the hydrogen atoms of thetert-butoxy group of docetaxel is replaced with deuterium (2/sup